Literature DB >> 33594448

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.

Dipenkumar Modi1, Vijendra Singh2, Seongho Kim3, Lois Ayash2, Abhinav Deol2, Voravit Ratanatharathorn2, Joseph P Uberti2.   

Abstract

A head-to-head comparison of outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens using thymoglobulin for GVHD prophylaxis is limited. We evaluated outcomes of 122 AML patients who received either busulfan (Bu)/fludarabine (Flu)/low-dose total body irradiation (TBI) as RIC (n = 64, 52%) or Bu/Flu as MAC (n = 58, 48%), and thymoglobulin 4.5 mg/kg total dose between day - 3 to - 1 for GVHD prophylaxis. Grades III-IV acute GVHD (aGVHD) was lower with Bu/Flu/TBI compared with Bu/Flu (6.2% vs 26.1%, p = 0.009). At 1 year, Bu/Flu/TBI was associated with similar chronic GVHD (41.2% vs 44.8%, p = 0.75), OS (61.9% vs 56.9%, p = 0.69), relapse rate (29.9% vs 20.7%, p = 0.24), relapse-free survival (52.8% vs 50%, p = 0.80), non-relapse mortality (17.4% vs 29.3%, p = 0.41), and GVHD-free relapse-free survival (24.2% vs 27.5%, p = 0.80) compared with Bu/Flu. Multivariable analysis did not reveal any difference in outcomes between both regimens. In summary, thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with RIC regimen. Both Bu/Flu/TBI and Bu/Flu conditioning regimens yielded similar survival.

Entities:  

Keywords:  Acute myeloid leukemia (AML); Allogeneic stem cell transplantation; Myeloablative conditioning regimen; Reduced intensity conditioning regimen; Thymoglobulin (ATG); Unrelated donor transplant

Year:  2021        PMID: 33594448     DOI: 10.1007/s00277-021-04445-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  33 in total

1.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

Authors:  Edwin P Alyea; Haesook T Kim; Vincent Ho; Corey Cutler; John Gribben; Daniel J DeAngelo; Stephanie J Lee; Sarah Windawi; Jerome Ritz; Richard M Stone; Joseph H Antin; Robert J Soiffer
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

Review 2.  Allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Jacopo Peccatori; Fabio Ciceri
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

3.  Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.

Authors:  Vikas Gupta; Andrew Daly; Jeffrey H Lipton; Wanda Hasegawa; Kathy Chun; Suzanne Kamel-Reid; Richard Tsang; Qi-long Yi; Mark Minden; Hans Messner; Thomas Kiss
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

4.  Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).

Authors:  J Y Cahn; M Labopin; A Schattenberg; J Reiffers; R Willemze; R Zittoun; A Bacigalupo; G Prentice; E Gluckman; P Hervé; A Gratwohl; N C Gorin
Journal:  Leukemia       Date:  1997-03       Impact factor: 11.528

Review 5.  TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.

Authors:  C E Hill-Kayser; J P Plastaras; Z Tochner; E Glatstein
Journal:  Bone Marrow Transplant       Date:  2010-11-29       Impact factor: 5.483

6.  Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.

Authors:  Herschel Wallen; Theodore A Gooley; H Joachim Deeg; John M Pagel; Oliver W Press; Frederick R Appelbaum; Rainer Storb; Ajay K Gopal
Journal:  J Clin Oncol       Date:  2005-04-11       Impact factor: 44.544

7.  Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Authors:  Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-21       Impact factor: 5.742

8.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Bart L Scott; Marcelo C Pasquini; Brent R Logan; Juan Wu; Steven M Devine; David L Porter; Richard T Maziarz; Erica D Warlick; Hugo F Fernandez; Edwin P Alyea; Mehdi Hamadani; Asad Bashey; Sergio Giralt; Nancy L Geller; Eric Leifer; Jennifer Le-Rademacher; Adam M Mendizabal; Mary M Horowitz; H Joachim Deeg; Mitchell E Horwitz
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

9.  Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

Authors:  D Modi; A Deol; S Kim; L Ayash; A Alavi; M Ventimiglia; D Bhutani; V Ratanatharathorn; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

10.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.

Authors:  Raymond Wong; Sergio A Giralt; Thomas Martin; Daniel R Couriel; Athanasios Anagnostopoulos; Chitra Hosing; Borje S Andersson; Pedro Cano; Munir Shahjahan; Cindy Ippoliti; Elihu H Estey; John McMannis; James L Gajewski; Richard E Champlin; Marcos de Lima
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.